基于树突状细胞的抗肿瘤疫苗研究进展  

Advance in antitumor vaccine based on dendritic cells

作　　者：高丽 李海霞 施维 杨晓梅[1,2] 卢小玲 GAO Li;LI Hai-Xia;SHI Wei;YANG Xiao-Mei;LU Xiao-Ling(School of Basic Medicine,Guangxi Medical University,Nanning 530021,China;International Nanobody Research Center of Guangxi,Nanning 530021,China;School of Stomatology,Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学基础医学院,南宁530021 [2]广西国际纳米抗体研究中心,南宁530021 [3]广西医科大学附属口腔医学院,南宁530021

出　　处：《生命科学》2021年第9期1125-1132,共8页Chinese Bulletin of Life Sciences

基　　金：国家重点研发计划(2019YFE0117300)。

摘　　要：树突状细胞(dendritic cells,DCs)是一类多功能抗原提呈细胞,在固有免疫和适应性免疫应答的启动及调控中发挥着重要作用。目前,大量研究表明机体可通过多种方式调动和调节DC的功能,从而增强其抗肿瘤作用。其中,以肿瘤抗原、肿瘤细胞裂解物或全肿瘤细胞作为刺激物致敏DC得到的DC疫苗,在临床前研究中展示出了可观的抗肿瘤效应,部分DC疫苗已进入临床试验阶段。该文将重点对基于DC的肿瘤疫苗制备方法、临床前及临床研究进展进行综述。As a type of multi-functional antigen presenting cells,dendritic cells(DCs)play an essential role in the initial and regulation of the innate immunity and the adaptive immunity.At present,increasing studies have shown that the functions of DCs could be motivated and regulated by several methods to enhance its anti-tumor cells.Among them,DC vaccines stimulated by tumor antigen,tumor cell lysates or whole tumor cells as antigens have shown considerable anti-tumor efficacy in preclinical studies,and some DC vaccines have entered clinical trials.This article focuses on the preparation methods,preclinical and clinical research progress of DC-based antitumoral vaccines.

关 键 词：树突状细胞 疫苗 抗肿瘤免疫 

分 类 号：R392[医药卫生—免疫学]